Avacta Group Share News (AVCT)

Avacta Group Information

Buy AVCT Shares
Add AVCT to Watchlist
Add AVCT to Alert

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 39.75

Bid: 39.50

Ask: 40.00

Change: -0.25 (-0.63%)

Spread: 0.50 (1.266%)

Open: 40.00

High: 40.00

Low: 39.75

Prev. Close: 40.00

Last checked at -

IN BRIEF: Avacta says no fundraising imminent after market speculation

Mon, 19th Jun 2023 12:43

Avacta Group PLC - Wetherby, England-based life sciences company developing targeted oncology drugs and diagnostics - Reponds to recent market speculation regarding a possible fundraising. Says no fundraising is imminent. Notes it has a strong cash balance of GBP27 million as at May 31 and expects strong new flow in the company months.

Current stock price: 104.75 pence, up 5.8% in London on Monday afternoon

12-month change: more than tripled from 28.99p

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

More News

24 Sep 2020 15:43

UK's Integumen unveils prototype COVID-19 breath test

LONDON, Sept 24 (Reuters) - Integumen, a British company that developed a system to detect the COVID-19 virus in waste water, said the same technology could be deployed in a personalised breath test that could become an effective tool in fighting...

21 Sep 2020 16:08

UK Earnings, Trading Statements Calendar - Next 7 Days

7 Sep 2020 14:28

IN BRIEF: Avacta To Launch SARS-CoV-2 Elisa Laboratory Test

7 Sep 2020 12:55

Avacta launching Covid-19 laboratory test

(Sharecast News) - Biotherapeutics company Avacta Group announced on Monday that it will launch an 'ELISA' laboratory test for the SARS-CoV-2 spike protein, to support global research efforts into the coronavirus that causes Covid-19.

2 Sep 2020 15:50

IN BRIEF: Avacta Expands Covid-19 Saliva Test Manufacturing Capacity

2 Sep 2020 13:37

Avacta signs Covid-19 test manufacturing deal with Abingdon

(Sharecast News) - Biotherapeutics company Avacta Group has entered into an agreement with Abingdon Health for the manufacture of its saliva-based rapid SARS-CoV-2 antigen test, it announced on Wednesday, as part of its ongoing expansion of manufacturing capacity.

18 Aug 2020 10:39

Latest Share Chat

Avacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

IN BRIEF: Avacta says no fundraising imminent after market speculation

UK's Integumen unveils prototype COVID-19 breath test

UK Earnings, Trading Statements Calendar - Next 7 Days

IN BRIEF: Avacta To Launch SARS-CoV-2 Elisa Laboratory Test

Avacta launching Covid-19 laboratory test

IN BRIEF: Avacta Expands Covid-19 Saliva Test Manufacturing Capacity

Avacta signs Covid-19 test manufacturing deal with Abingdon

Avacta Expands Development Agreement With LG Chem Life Sciences

IN BRIEF: Avacta Not Involved With Medusa 19's Covid Antibody Test

IN BRIEF: Avacta Names New Life Sciences Chief Development Officer

Avacta to collaborate with Liverpool School of Tropical Medicine on Covid-19 test

UK WINNERS & LOSERS SUMMARY: Hikma Shines After Raising Sales Guidance

Avacta Collaborates With Liverpool School For Covid-19 Test Validation

IN BRIEF: Avacta Appoints BBI Solutions To Manufacture Covid Test Kit

Avacta appoints BBI Solutions as manufacturing partner for Covid-19 antigen test

IN BRIEF: Avacta Expands Partnership With Daewoong Pharmaceutical

Latest Share Chat

Avacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Avacta says no fundraising imminent after market speculation

Login to your account

Quickpicks are a member only feature

Login to your account